Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.80 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.80 |
| ▸ | MEN1 | O00255 | 5/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.80 |
| ▸ | LMNA | P02545 | 4/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.80 |
| ▸ | APP | P05067 | 3/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.76 |
| ▸ | HPGD | P15428 | 2/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 5/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25265052 | 1.00 | MAPT (0.80) | MAPTABCG2MEN1KMT2ALMNA | |
| SCHEMBL30383556 | 1.00 | MAPT (0.80) | MAPTABCG2MEN1KMT2ALMNA | |
| SCHEMBL30383705 | 0.92 | ABCG2 (0.84) | MAPTABCG2MEN1KMT2ALMNA | |
| SCHEMBL2129845 | 0.92 | ABCG2 (0.84) | MAPTABCG2MEN1KMT2ALMNA | |
| SCHEMBL2129839 | 0.92 | ABCG2 (0.84) | MAPTABCG2MEN1KMT2ALMNA | |
| SCHEMBL5088006 | 0.89 | MAPT (0.76) | MAPTABCG2MEN1KMT2ALMNA | |
| SCHEMBL5087997 | 0.89 | MAPT (0.76) | MAPTABCG2MEN1KMT2ALMNA | |
| SCHEMBL25189208 | 0.89 | ABCG2 (1.00) | MAPTABCG2MEN1KMT2ALMNA | |
| SCHEMBL634187 | 0.89 | ABCG2 (1.00) | MAPTABCG2MEN1KMT2ALMNA | |
| SCHEMBL30384538 | 0.89 | ABCG2 (1.00) | MAPTABCG2MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MAPT 3297/4885ABCG2 1606/4885MEN1 3367/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885ABCG2 3622/4885MEN1 2457/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885ABCG2 3622/4885MEN1 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.